FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802962189> ?p ?o ?g. }

• W2802962189 endingPage "33" @default.
• W2802962189 startingPage "33" @default.
• W2802962189 abstract "PURPOSE: In select patients, vascularized composite allotransplantation (VCA) offers functional and aesthetic outcomes superior to autologous reconstruction. However, its role in the reconstructive armamentarium is limited by the need for life-long immunosuppression. Furthermore, some studies have suggested that skin-containing VCA requires greater maintenance immunosuppression than solid organ transplants due to higher antigenicity. This study evaluates trends of maintenance immunosuppression in skin-containing VCA recipients and kidney recipients to determine differences in therapeutic risk. METHODS: VCA immunosuppression data were collected through a review of hand and face transplant literature. Kidney transplant immunosuppression data were collected through an institutional review board-approved retrospective chart review of a randomly selected group of 100 patients whose transplants were performed between 1997 and 2016. Data from patients younger than 18, patients not receiving triple maintenance immunosuppression therapy, and patients with missing immunosuppression information were excluded from the analysis. Prednisone doses (mg/day) and mycophenolate mofetil (MMF) doses (gm/day) were compared between VCA and kidney recipients at predefined follow-up intervals (<1, 1–5, and >5 years). Tacrolimus target trough levels (TTTL) were stratified into our institution’s kidney transplant risk-based target ranges (low risk: 4–6 ng/ml, high risk: 6–8 ng/ml) or higher (>8 ng/ml). The distribution of VCA recipient and kidney recipient TTTL was calculated at follow-up intervals of 1–5 and >5 years within each cohort. RESULTS: Immunosuppression data were available for 57 VCA recipients and 98 kidney recipients. There were no significant differences in prednisone doses between groups at all follow-up intervals. While the mean MMF dose of VCA recipients was significantly greater than that of kidney recipients at less than 1 year (1.71 ± 0.58 vs. 1.16 ± 0.55 gm/day; p=0.01), there was no significant difference at subsequent follow-up intervals. For VCA recipients, there was a significant difference (p=0.02) in TTTL distribution over the three predefined therapeutic ranges (4–6 ng/ml, 6–8 ng/ml, >8 ng/ml, respectively) between 1–5 years (24.0%, 20.0%, 56.0%, respectively) and greater than 5 years (28.6%, 42.9%, 28.6%). Kidney recipients showed no significant difference in TTTL distribution over the three defined therapeutic ranges (4–6 ng/ml, 6–8 ng/ml, and >8 ng/ml) between the follow-up intervals. CONCLUSION: At longer follow-up, VCA and kidney recipients receive comparable MMF and prednisone doses. In addition, the majority of VCA recipients are treated with TTTL similar to kidney recipients after 5 years. These findings suggest that VCA recipients may not be subject to a higher level of dose-related immunosuppressive therapeutic risk than kidney recipients at longer follow-up. While the benefits of VCA have proven difficult to quantify, a detailed understanding of therapeutic risk may serve to enhance the informed consent process. Transparent outcome reports are warranted to determine safe and effective strategies for minimization of immunosuppression in VCA. A.K. Manjunath: None. R.S. Kantar: None. M.J. Cammarata: None. A. Jacoby: None. W.J. Rifkin: None. B.E. Gelb: None. R. Diaz-Siso: None. E.D. Rodriguez: None." @default.
• W2802962189 created "2018-05-17" @default.
• W2802962189 creator A5006002578 @default.
• W2802962189 creator A5006176860 @default.
• W2802962189 creator A5065875238 @default.
• W2802962189 creator A5070310325 @default.
• W2802962189 creator A5070830539 @default.
• W2802962189 creator A5081800438 @default.
• W2802962189 creator A5085447344 @default.
• W2802962189 creator A5088082671 @default.
• W2802962189 date "2018-04-01" @default.
• W2802962189 modified "2023-10-18" @default.
• W2802962189 title "Abstract 42" @default.
• W2802962189 doi "https://doi.org/10.1097/01.gox.0000533907.18022.e9" @default.
• W2802962189 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5959676" @default.
• W2802962189 hasPublicationYear "2018" @default.
• W2802962189 type Work @default.
• W2802962189 sameAs 2802962189 @default.
• W2802962189 citedByCount "0" @default.
• W2802962189 crossrefType "journal-article" @default.
• W2802962189 hasAuthorship W2802962189A5006002578 @default.
• W2802962189 hasAuthorship W2802962189A5006176860 @default.
• W2802962189 hasAuthorship W2802962189A5065875238 @default.
• W2802962189 hasAuthorship W2802962189A5070310325 @default.
• W2802962189 hasAuthorship W2802962189A5070830539 @default.
• W2802962189 hasAuthorship W2802962189A5081800438 @default.
• W2802962189 hasAuthorship W2802962189A5085447344 @default.
• W2802962189 hasAuthorship W2802962189A5088082671 @default.
• W2802962189 hasBestOaLocation W28029621891 @default.
• W2802962189 hasConcept C126322002 @default.
• W2802962189 hasConcept C126894567 @default.
• W2802962189 hasConcept C128057223 @default.
• W2802962189 hasConcept C141071460 @default.
• W2802962189 hasConcept C2778720950 @default.
• W2802962189 hasConcept C2780091579 @default.
• W2802962189 hasConcept C2780252810 @default.
• W2802962189 hasConcept C2780303639 @default.
• W2802962189 hasConcept C2909675724 @default.
• W2802962189 hasConcept C2911091166 @default.
• W2802962189 hasConcept C2994498544 @default.
• W2802962189 hasConcept C71924100 @default.
• W2802962189 hasConceptScore W2802962189C126322002 @default.
• W2802962189 hasConceptScore W2802962189C126894567 @default.
• W2802962189 hasConceptScore W2802962189C128057223 @default.
• W2802962189 hasConceptScore W2802962189C141071460 @default.
• W2802962189 hasConceptScore W2802962189C2778720950 @default.
• W2802962189 hasConceptScore W2802962189C2780091579 @default.
• W2802962189 hasConceptScore W2802962189C2780252810 @default.
• W2802962189 hasConceptScore W2802962189C2780303639 @default.
• W2802962189 hasConceptScore W2802962189C2909675724 @default.
• W2802962189 hasConceptScore W2802962189C2911091166 @default.
• W2802962189 hasConceptScore W2802962189C2994498544 @default.
• W2802962189 hasConceptScore W2802962189C71924100 @default.
• W2802962189 hasIssue "4S" @default.
• W2802962189 hasLocation W28029621891 @default.
• W2802962189 hasLocation W28029621892 @default.
• W2802962189 hasLocation W28029621893 @default.
• W2802962189 hasOpenAccess W2802962189 @default.
• W2802962189 hasPrimaryLocation W28029621891 @default.
• W2802962189 hasRelatedWork W2087821141 @default.
• W2802962189 hasRelatedWork W2088085536 @default.
• W2802962189 hasRelatedWork W2131345312 @default.
• W2802962189 hasRelatedWork W2400889191 @default.
• W2802962189 hasRelatedWork W2571829990 @default.
• W2802962189 hasRelatedWork W2772375047 @default.
• W2802962189 hasRelatedWork W3088212660 @default.
• W2802962189 hasRelatedWork W3183386452 @default.
• W2802962189 hasRelatedWork W4240284178 @default.
• W2802962189 hasRelatedWork W2593051879 @default.
• W2802962189 hasVolume "6" @default.
• W2802962189 isParatext "false" @default.
• W2802962189 isRetracted "false" @default.
• W2802962189 magId "2802962189" @default.
• W2802962189 workType "article" @default.